Biomarkers of drug-induced adverse events

Expert Review of Clinical Pharmacology

Volumn 1, Issue 1, 2008, Pages 81-91

  Mendrick, Donna L ^a   Daniels, Kellye K ^a  

^a Gene Logic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALKYLATING AGENT; AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; ARISTOLOCHIC ACID; ATRIAL NATRIURETIC FACTOR; BILIRUBIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; CREATININE; DIHYDRALAZINE; FENFLURAMINE; GENTAMICIN; HALOTHANE; LACTATE DEHYDROGENASE; LIPOCALIN; METHOTREXATE; MYOGLOBIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITROGEN; ROFECOXIB; ROSIGLITAZONE; TIENILIC ACID; TOLL LIKE RECEPTOR 4; TORCETRAPIB; TROGLITAZONE; TROPONIN; UNINDEXED DRUG; UREA;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD VESSEL INJURY; CARDIOTOXICITY; CELL DEATH; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EARLY DIAGNOSIS; HEALTH CARE COST; HEART FAILURE; HEART INJURY; HUMAN; IMMUNE MEDIATED INJURY; KIDNEY INJURY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; NEPHROTOXICITY; NON INVASIVE MEASUREMENT; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PSORIASIS; REVIEW; TISSUE INJURY; UREA NITROGEN BLOOD LEVEL;

EID: 38348998880     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.1.81     Document Type: Review

References (70)

1. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.BMJ 332, 1177-1181 (2006).
2. Minino AM, Heron MP, Smith BL.Deaths: Preliminary Data for 2004. (Volume 54, number 19). Centers for Disease Control and Prevention, GA, USA (2006).
3. Mendrick DL. Current trends and strategic directions in the use of pharmacogenomics to identify translational biomarkers.Curr. Opin. Drug Discov. Devel. 10, 37-42 (2007).
4. Park K, Williams DP, Naisbitt DJ, Kitteringham NR, Pirmohamed M. Investigation of toxic metabolites during drug development.Toxicol. Appl. Pharmacol. 207, 425-434 (2005).
5. Kaplowitz N. Idiosyncratic drug hepatotoxicity.Nat. Rev. Drug Discov. 4, 489-499 (2005).
6. Farrell GC. Drug-induced hepatic injury. J. Gastroenterol. Hepatol. 12, S242-S250 (1997).
7. Andrade RJ, Robles M, Fernandez-Castaner A et al. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J. Gastroenterol. 13, 329-340 (2007).
8. Titcomb CP Jr. Liver function tests: what is the risk? J. Insur. Med. 35, 26-35 (2003).
9. O'Grady JG. Broadening the view of acetaminophen hepatotoxicity. Hepatology 42, 1252-1254 (2005).
10. Larson AM, Polson J, Fontana RJ et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42, 1364-1372 (2005).
11. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947-954 (2002).
12. Amacher DE. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul. Toxicol. Pharmacol. 27, 119-130 (1998).
13. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 172, 367-379 (2005).
14. Aithal GP, Haugk B, Das S et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment. Pharmacol. Ther. 19, 391-399 (2004).
15. Lacour S, Gautier JC, Pallardy M, Roberts R. Cytokines as potential biomarkers of liver toxicity. Cancer Biomark. 1, 29-39 (2005).
16. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32, 247-255 (2000).
17. Mukherjee S, Sorrell MF. Noninvasive tests for liver fibrosis. Semin. Liver Dis. 26, 337-347 (2006).
18. Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 29, 567-586 (2006).
19. Feenstra J, Grobbee DE, Remme WJ, Stricker BHC. Drug-induced heart failure. J. Am. Coll. Cardiol. 33, 1152-1162 (1999).
20. Wallace KB, Hausner E, Herman E et al. Serum troponins as biomarkers of drug-induced. Toxicol. Pathol. 32, 106-121 (2004).
21. Walker DB. Serum chemical biomarkers of cardiac injury for nonclinical safety testing. Toxicol. Pathol. 34, 94-104 (2006).
22. Dolci A, Panteghini M. The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin. Chim. Acta 369, 179-187 (2006).
23. Eriksson S, Wittfooth S, Pettersson K. Present and future biochemical markers for detection of acute coronary syndrome. Crit. Rev. Clin. Lab. Sci. 43, 427-495 (2006).
24. Gaze DC, Collinson PO. Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection. Expert Opin. Drug Metab. Toxicol. 1, 715-725 (2005).
25. O'Brien PJ. Blood cardiac troponin in toxic myocardial injury: archetype of a translational safety biomarker. Expert Rev. Mol. Diagn. 6, 685-702 (2006).
26. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J. Am. Coll. Cardiol. 48, 1-11 (2006).
27. Adamcova M, Simunek T, Kaiserova H et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 237, 218-228 (2007).
28. Solaro RJ. Arteaga GM. Heart failure, ischemia/reperfusion injury and cardiac troponin. Adv. Myocardiol. 592, 191-200 (2007).
29. Erkus B, Demirtas S. Yarpuzlu AA et al. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr. 96, 506-509 (2007).
30. Okumura H, Iuchi K, Yoshida T et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 104, 158-163 (2000).
31. Hama N, Itoh H, Shirakami G et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92, 1558-1564 (1995).
32. Brott DA, Jones HB, Gould S et al. Current status and future directions for diagnostic markers of drug-induced vascular injury. Cancer Biomark. 1, 15-28 (2005).
33. Kerns W, Schwartz L, Blanchard K et al. Drug-induced vascular injury-a quest for biomarkers. Toxicol. Appl. Pharmacol. 203, 62-87 (2005).
34. Palmer BF, Henrich WL. Toxic nephropathy. In: Brenner & Rector's The Kidney (7th Edition). Brenner BM (Ed.). Saunders. PA, USA 1625-1658 (2004).
35. Perazella MA. Drug-induced nephropathy: an update. Expert Opin.Drug Saf. 4, 689-706 (2005).
36. Vaidya VS, Bonventre JV. Mechanistic biomarkers for cytotoxic acute kidney injury. Expert Opin. Drug Metab. Toxicol. 2, 697-713 (2006).
37. Silkensen JR, Kasiske BL. Laboratory assessment of kidney disease: clearance, urinalysis, and kidney biopsy. In: Brenner and Rector's The Kidney (7th Edition). Brenner BM (Ed.). Saunders, PA, USA 1107-1150 (2004).
38. Ichimura T, Bonventre JV, Bailly V et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273, 4135-4142 (1998).
39. Davis JW, Goodsaid FM, Bral CM et al. Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 200, 16-26 (2004).
40. Amin RP, Vickers AE, Sistare F et al. Identification of putative gene based markers of renal toxicity. Environ. Health Perspect. 112, 465-479 (2004).
41. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244 (2002).
42. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal Physiol. 290, F517-F529 (2006).
43. Liangos O, Perianayagam MC, Vaidya VS et al. Urinary N-acetyl-β-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J. Am. Soc. Nephrol. 18, 904-912 (2007).
44. van Timmeren MM, van den Heuvel MC, Bailly V et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J. Pathol. 212, 209-217 (2007).
45. Schmidt-Ott KM. Mori K, Li JY et al. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 18, 407-413 (2007).
46. Mishra J, Mori K, Ma Q et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 24, 307-315 (2004).
47. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem. J. 31, 433-441 (1999).
48. Fernandez CA, Yan L, Louis G et al. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. 11, 5390-5395 (2005).
49. El-Achkar TM, Huang X, Plotkin Z et al. Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney. Am. J. Physiol. Renal Physiol. 290, F1034-F1043 (2006).
50. Zager RA, Johnson AC, Lund S, Randolph-Habecker J. Toll-like receptor (TLR4) shedding and depletion: acute proximal tubular cell responses to hypoxic and toxic injury. Am. J. Physiol. Renal Physiol. 292(1), F304-F312(2007).
51. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 6, 16-21 (2006).
52. Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol. Sci. 27, 498-502 (2006).
53. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 20, 163-175 (2006).
54. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf. 27, 145-172 (2004).
55. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2, S30-S37 (2005).
56. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
57. Fries S, Grosser T, Price TS et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130, 55-64 (2006).
58. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
59. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
60. Giacomini KM, Brett CM, Altman RB et al. The Pharmacogenetics Research Network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81, 328-345 (2007).
61. Hultin-Rosenberg L, Jagannathan S, Nilsson KC et al. Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 36, 1122-1139 (2006).
62. Martin R, Rose D, Yu K, Barros S. Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7, 1003-1016 (2006).
63. Fielden MR, Eynon BP, Natsoulis G et al., A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol. Pathol. 33, 675-683 (2005).
64. Mendrick DL, Daniels KK. From the bench to the clinic and back again: translational biomarker discovery using in silico mining of pharmacogenomic data. Biomarkers in Medicine 1(2), 319-333 (2007).
65. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7, 773-782 (2006).
66. Phillips KA. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff. (Millwood) 25, 1271-1280 (2006).
67. Pirmohamed M, James S, Meakin et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15-19 (2004).
68. Evans RW, Williams GE, Baron HM et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am. J. Transplant. 5, 1553-1558 (2005).
69. Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nat. Rev. Drug Discov. 4, 500-509 (2005).
70. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5, 1139-1149 (2004).